Cargando…
Fenofibrate and Impaired Taste Perception in Type 2 Diabetes
Patient: Female, 65-year-old Final Diagnosis: Type 2 diabetes Symptoms: Loss of sweet taste Medication: Fenofibrate Clinical Procedure: Drug challenge/dechallenge/rechallenge Specialty: Endocrinology and Metabolic OBJECTIVE: Unusual clinical course BACKGROUND: Although reduced sweet taste perception...
Autor principal: | |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
International Scientific Literature, Inc.
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7684425/ https://www.ncbi.nlm.nih.gov/pubmed/33214542 http://dx.doi.org/10.12659/AJCR.927647 |
_version_ | 1783613012678017024 |
---|---|
author | Davis, Timothy M.E. |
author_facet | Davis, Timothy M.E. |
author_sort | Davis, Timothy M.E. |
collection | PubMed |
description | Patient: Female, 65-year-old Final Diagnosis: Type 2 diabetes Symptoms: Loss of sweet taste Medication: Fenofibrate Clinical Procedure: Drug challenge/dechallenge/rechallenge Specialty: Endocrinology and Metabolic OBJECTIVE: Unusual clinical course BACKGROUND: Although reduced sweet taste perception has been found in studies of clofibrate in healthy volunteers, this phenomenon has not been reported for the chemically related and more widely used drug fenofibrate. CASE REPORT: A 65-year-old woman with insulin-treated type 2 diabetes was initiated on fenofibrate for worsening diabetic retinopathy. She subsequently developed a marked loss of sweet taste perception. After 3 months of fenofibrate, her glycemic control had improved and her insulin requirements had decreased, probably as a result of anorexia. Her renal function had also worsened. Dechallenge resulted in near normalization of sweet taste and restoration of her pretreatment renal function 2 weeks later. Rechallenge provoked recurrence of severely impaired sweet taste perception, which led to permanent discontinuation of fenofibrate. CONCLUSIONS: This case shows that altered sweet taste perception is a potential clinically significant adverse effect of fenofibrate therapy. There is increasing interest in the function of sweet taste receptors, which are recognized as having a broader role in cellular function and inflammation in tissues such as the kidney and retina that are relevant to type 2 diabetes and its complications. |
format | Online Article Text |
id | pubmed-7684425 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | International Scientific Literature, Inc. |
record_format | MEDLINE/PubMed |
spelling | pubmed-76844252020-12-03 Fenofibrate and Impaired Taste Perception in Type 2 Diabetes Davis, Timothy M.E. Am J Case Rep Articles Patient: Female, 65-year-old Final Diagnosis: Type 2 diabetes Symptoms: Loss of sweet taste Medication: Fenofibrate Clinical Procedure: Drug challenge/dechallenge/rechallenge Specialty: Endocrinology and Metabolic OBJECTIVE: Unusual clinical course BACKGROUND: Although reduced sweet taste perception has been found in studies of clofibrate in healthy volunteers, this phenomenon has not been reported for the chemically related and more widely used drug fenofibrate. CASE REPORT: A 65-year-old woman with insulin-treated type 2 diabetes was initiated on fenofibrate for worsening diabetic retinopathy. She subsequently developed a marked loss of sweet taste perception. After 3 months of fenofibrate, her glycemic control had improved and her insulin requirements had decreased, probably as a result of anorexia. Her renal function had also worsened. Dechallenge resulted in near normalization of sweet taste and restoration of her pretreatment renal function 2 weeks later. Rechallenge provoked recurrence of severely impaired sweet taste perception, which led to permanent discontinuation of fenofibrate. CONCLUSIONS: This case shows that altered sweet taste perception is a potential clinically significant adverse effect of fenofibrate therapy. There is increasing interest in the function of sweet taste receptors, which are recognized as having a broader role in cellular function and inflammation in tissues such as the kidney and retina that are relevant to type 2 diabetes and its complications. International Scientific Literature, Inc. 2020-11-20 /pmc/articles/PMC7684425/ /pubmed/33214542 http://dx.doi.org/10.12659/AJCR.927647 Text en © Am J Case Rep, 2020 This work is licensed under Creative Common Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0 (https://creativecommons.org/licenses/by-nc-nd/4.0/) ) |
spellingShingle | Articles Davis, Timothy M.E. Fenofibrate and Impaired Taste Perception in Type 2 Diabetes |
title | Fenofibrate and Impaired Taste Perception in Type 2 Diabetes |
title_full | Fenofibrate and Impaired Taste Perception in Type 2 Diabetes |
title_fullStr | Fenofibrate and Impaired Taste Perception in Type 2 Diabetes |
title_full_unstemmed | Fenofibrate and Impaired Taste Perception in Type 2 Diabetes |
title_short | Fenofibrate and Impaired Taste Perception in Type 2 Diabetes |
title_sort | fenofibrate and impaired taste perception in type 2 diabetes |
topic | Articles |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7684425/ https://www.ncbi.nlm.nih.gov/pubmed/33214542 http://dx.doi.org/10.12659/AJCR.927647 |
work_keys_str_mv | AT davistimothyme fenofibrateandimpairedtasteperceptionintype2diabetes |